Head to Head Survey: Surgical Care Affiliates (SCAI) vs. Cancer Genetics (CGIX)
Surgical Care Affiliates (NASDAQ: SCAI) and Cancer Genetics (NASDAQ:CGIX) are both healthcare facilities & services – nec companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, risk, valuation, dividends and analyst recommendations.
Earnings & Valuation
This table compares Surgical Care Affiliates and Cancer Genetics’ top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||NetIncome||Earnings Per Share||Price/Earnings Ratio|
|Surgical Care Affiliates||N/A||N/A||N/A||$0.86||64.97|
|Cancer Genetics||$27.05 million||2.16||-$15.80 million||($0.97)||-3.04|
Surgical Care Affiliates has higher revenue, but lower earnings than Cancer Genetics. Cancer Genetics is trading at a lower price-to-earnings ratio than Surgical Care Affiliates, indicating that it is currently the more affordable of the two stocks.
This is a breakdown of current recommendations and price targets for Surgical Care Affiliates and Cancer Genetics, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Surgical Care Affiliates||0||2||0||0||2.00|
Surgical Care Affiliates currently has a consensus price target of $50.00, indicating a potential downside of 10.51%. Cancer Genetics has a consensus price target of $6.00, indicating a potential upside of 103.39%. Given Cancer Genetics’ stronger consensus rating and higher possible upside, analysts plainly believe Cancer Genetics is more favorable than Surgical Care Affiliates.
Institutional & Insider Ownership
15.6% of Cancer Genetics shares are held by institutional investors. 3.3% of Surgical Care Affiliates shares are held by company insiders. Comparatively, 21.3% of Cancer Genetics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
This table compares Surgical Care Affiliates and Cancer Genetics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Surgical Care Affiliates||21.52%||13.07%||12.83%|
Cancer Genetics beats Surgical Care Affiliates on 6 of the 10 factors compared between the two stocks.
About Surgical Care Affiliates
Surgical Care Affiliates, Inc. is a provider of solutions to physicians, health plans and health systems to optimize surgical care. The Company offers tools and systems in the areas of clinical benchmarking, clinical best practices, operating efficiency, care coordination and supply chain management. As of December 31, 2016, the Company operated a network of surgical facilities in the United States, which included 197 ambulatory surgery centers (ASCs) and seven surgical hospitals in partnership with approximately 3,000 physician partners. The Company’s operations consist of its ownership and management of ASCs and surgical hospitals. Its ASCs provide the facilities, equipment, supplies and clinical support staff necessary to provide non-emergency surgical services to patients not requiring hospitalization. Its surgical hospitals allow physicians to perform a range of surgical procedures, including surgeries, and allow patients to stay in the hospital for several nights to recover.
About Cancer Genetics
Cancer Genetics, Inc. is a United States-based company, which is engaged in the field of personalized medicine. The Company offers diagnostic products and services that enable precision medicine in the field of oncology through molecular markers and diagnostics. The Company offers a range of laboratory services that provide genomic and biomarker information. Its Select One Clinical Trials program provides a range of integrated and dynamic clinical trial services for both oncology and non-oncology genetic testing for Phase I-III trials along with ancillary services, including bioinformatics, biorepository and trials logistic support. The Company is developing a global footprint with locations in the United States, India and China. It also offers a portfolio of genotyping services, with access to over 400 validated genotyping assays, including Phase I and Phase II drug metabolizing enzymes, transporters, and receptors, and over 30 validated gene expression assays.
Receive News & Stock Ratings for Surgical Care Affiliates Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Surgical Care Affiliates Inc and related stocks with our FREE daily email newsletter.